Innate: agreement with IFLI in follicular lymphoma

(CercleFinance.com) - Innate Pharma announces an agreement with the Institute for Follicular Lymphoma Innovation (IFLI) to explore the clinical potential of IPH6501, its anti-CD20 ANKET, in follicular lymphoma.


Patients with relapsed and/or refractory follicular lymphoma will be included in the ongoing Phase 1/2 trial evaluating IPH6501 in patients with CD20-expressing non-Hodgkin's lymphoma.

To support this clinical trial, IFLI will invest $3 million in new Innate shares, at a price of €1.56 each. It may also invest up to $4.9 million in the same form, depending on the achievement of certain milestones.

Copyright (c) 2024 CercleFinance.com. All rights reserved.